NimbleGen Files for IPO; Pricing Not Yet Determined | GenomeWeb
NEW YORK (GenomeWeb News) - NimbleGen has filed for an initial public offering with the Securities and Exchange Commission, the company said Friday.
The number and prices of shares have not yet been determined.
NimbleGen is a microarray developer that specializes in products and services for comparative genomic hybridization, chromatin immunoprecipitation arrays, comparative genome sequencing, and expression analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.